Pharmaceutical Contract Manufacturing Market

Chapter Outlines

Chapter 2 provides an executive summary of the key insights captured in our research. The summary offers a high-level view on the likely evolution of pharmaceutical contract manufacturing services market in China, in the short-mid and long term.

Chapter 3 is a general introduction to various type of manufacturers engaged in the pharmaceutical domain. It also includes a brief overview on the concept of contract manufacturing and a general discussion on the evolution of contract services in the pharmaceutical industry. The chapter features an exhaustive list of services offered by CMOs. Further, it highlights the current contract manufacturing scenario in China, along with the advantages and disadvantages associated with choosing a China based CMO as a partner. 

Chapter 4 is a case study comparing the key characteristics of large and small molecule drugs, along with information on the steps involved in their respective manufacturing processes. In addition, it highlights the information on the key manufacturing challenges associated with small molecules and large molecules.

Chapter 5 provides an overview of the pharmaceutical contract manufacturing landscape of companies that claim to offer small molecule API, intermediate and FDF manufacturing services. It includes analysis based on a number of relevant parameters, such as year of establishment, company size, location of headquarters, type of product (APIs, intermediates and FDFs), type of FDFs, type of packaging (primary packaging and secondary packaging), and number of China-based manufacturing facilities.

Chapter 6 provides a detailed landscape of pharmaceutical manufacturing facilities in China. It includes analysis and map representations based on location of these facilities, highlighting key provinces as manufacturing hubs.  

Chapter 7 features a brief discussion on the regulatory guidelines related to the pharmaceutical manufacturing in China. It also highlights points related to the various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China.

Chapter 8 includes detailed profiles of key players that offer a diverse range of capabilities for the manufacturing of pharmaceutical products in China. Each profile features a brief overview of the company, details related to its manufacturing-related service portfolio, details related to its manufacturing facilities, recent developments, and an informed future outlook.

Chapter 9 provides a detailed analysis of pharmaceutical manufacturing related initiatives of the top 10 big pharma players (shortlisted from the top companies of 2019 by revenues), featuring a [A] facility investment analysis with detailed information on R&D centers and manufacturing facilities in established and emerging regions of China, [B] Harvey ball framework presenting the summary of manufacturing initiatives undertaken by big pharma players in China, and [C] heat map representation representing the year-wise distribution of the initiatives undertaken by each company.

Chapter 10 represents a case study of the key recent activities of the CMOs from 2017 to February 2020 (including partnerships and acquisitions) pertaining to the manufacturing of pharmaceutical drugs. It includes analysis based on several parameters, such as year of partnership, type of partnership and geographical activity of the partnerships.

Chapter 11 features an estimate of the overall installed reactor capacity of CMOs. The analysis based on the individual reactor capacities of various industry stakeholders, taking into consideration parameters, such as company size (small-sized, mid-sized, large and very large), and location of the manufacturing facility (Eastern China, Southern China and Northern China).

Chapter 12 presents a discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.

Chapter 13 features an elaborate market forecast analysis highlighting the likely growth of pharmaceutical contract manufacturing market in China, till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] key geographical regions (Eastern China, Southern China, Northern China), [B] type of product (API and drug product), [C] type of drug product (solid, liquid / semi-solid, injectables, others), [D] scale of operation (clinical and commercial), [E] company size (small-sized, mid-sized, large / very large). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Chapter 14 highlights the effect of coronavirus outbreak on the global pharmaceutical industry. It includes a brief discussion on the short-term and long-term impact of COVID-19 upsurge on the supply chain and market opportunity for drug developers and CMOs. In addition, it includes a brief section on strategies and action plans that pharma companies are likely to adopt in order to prepare for supply chain disruptions in future. 

Chapter 15 is a summary of the overall report. It includes key takeaways related to research and analysis from the report in an infographic format.

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of the Pharmaceutical Contract Manufacturing 
3.3. Evolution of the Pharmaceutical Contract Manufacturing Industry
3.3.1. Traditional CMOs
3.3.2. Modern CMOs
3.4 Need for Outsourcing in the Pharmaceutical Industry
3.5. Services Offered by CMOs
3.6. Pharmaceutical Contract Manufacturing Scenario in China
3.7. Advantages and Challenges associated with Outsourcing Pharmaceutical Manufacturing to China-based CMOs

4. CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES
4.1. Chapter Overview
4.2. Small Molecule and Large Molecule Drugs / Therapies
4.2.1. Comparison of Key Characteristics
4.2.2. Comparison of Manufacturing Processes
4.2.3. Comparison of Key Manufacturing-related Challenges

5. MARKET OVERVIEW
5.1. Chapter Overview
5.2. Chinese Pharmaceutical CMOs with Manufacturing Facilities in China: List of Companies
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Product (API and FDF)
5.2.4.1. Analysis by Type of Product and Location of Headquarters
5.2.5. Analysis by Highest Scale of Operation
5.2.6. Analysis by Type of FDF
5.2.6.1. Analysis by Type of Solid FDF
5.2.6.2. Analysis by Type of Liquid FDF
5.2.6.3. Analysis by Type of Powder FDF
5.2.6.4. Analysis by Type of Semi-Solid FDF
5.2.6.5. Analysis by Type of FDF and Region
5.2.7. Analysis by Type of Primary Packaging

5.3. Non-Chinese Pharmaceutical CMOs with Manufacturing Facilities in China: List of Companies
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters
5.3.4. Analysis by Type of Product (API and FDF)
5.3.4.1. Analysis by Type of Product and Region
5.3.5. Analysis by Highest Scale of Operation
5.3.6. Analysis by Type of FDF
5.3.6.1. Analysis by Type of Solid FDF
5.3.6.2. Analysis by Type of Liquid FDF
5.3.6.3. Analysis by Type of Powder FDF
5.3.6.5. Analysis by Type of FDF and Region

6. MANUFACTURING FACILITIES OF PHARMACEUTICAL CMOs IN CHINA
6.1. Chapter Overview
6.2. Pharmaceutical CMO Manufacturing Facilities in China
6.2.1. Facilities in Eastern China
6.2.1.1. Pharmaceutical CMO Manufacturing Facilities in Eastern China: Analysis by Location of Facility
6.2.1.2. Pharmaceutical CMO Manufacturing Facilities in Eastern China: Analysis by Company Size and Type of Product
6.2.2. Facilities in Northern China
6.2.2.1. Pharmaceutical CMO Manufacturing Facilities in Northern China: Analysis by Location of Facility
6.2.2.2. Pharmaceutical CMO Manufacturing Facilities in Northern China: Analysis by Company Size and Type of Product
6.2.3. Facilities in Southern China
6.2.3.1. Pharmaceutical CMO Manufacturing Facilities in Southern China: Analysis by Location of Facility
6.2.3.2. Pharmaceutical CMO Manufacturing Facilities in Southern China: Analysis by Company Size and Type of Product

7. PHARMACEUTICAL MANUFACTURING REGULATIONS IN CHINA
7.1. Chapter Overview
7.1.1. Health Authorities in China
7.1.2. Overview of Regulatory Guidelines in China

8. COMPANY PROFILES
8.1. Chapter Overview
8.2. 2Y-Chem
8.2.1. Company Overview
8.2.2. Service Portfolio
8.2.3. Recent Developments and Future Outlook

8.3. Aurisco Pharmaceutical
8.3.1. Company Overview
8.3.2. Service Portfolio
8.3.3. Recent Developments and Future Outlook

8.4. ChemPartner
8.4.1. Company Overview
8.4.2. Service Portfolio
8.4.4. Recent Developments and Future Outlook

8.5. Dorrapharma
8.5.1. Company Overview
8.5.2. Service Portfolio
8.5.4. Recent Developments and Future Outlook

8.6. Hubei Biocause Pharmaceutical
8.6.1. Company Overview
8.6.2. Service Portfolio
8.6.3. Recent Developments and Future Outlook

8.7. Infoark
8.7.1. Company Overview
8.7.2. Service Portfolio
8.7.3. Recent Developments and Future Outlook

8.8. Ningbo Menovo Pharmaceutical
8.8.1. Company Overview
8.8.2. Service Portfolio
8.8.3. Recent Developments and Future Outlook

8.9. Shandong Xinhua Pharmaceutical
8.9.1. Company Overview
8.9.2. Service Portfolio
8.9.3. Recent Developments and Future Outlook

8.10. Shanghai Acebright Pharmaceuticals
8.10.1. Company Overview
8.10.2. Service Portfolio
8.10.3. Recent Developments and Future Outlook

8.11. STA Pharmaceutical
8.11.1. Company Overview
8.11.2. Service Portfolio
8.11.3. Recent Developments and Future Outlook

8.12. Zhejiang Huahai Pharmaceutical
8.12.1. Company Overview
8.12.2. Service Portfolio
8.12.4. Recent Developments and Future Outlook

9. BIG PHARMA INITIATIVES IN CHINA
9.1. Chapter Overview
9.2. Big Pharma Players: List of Initiatives
9.2.1. Analysis by Number of Initiatives
9.2.2. Analysis by Year of Initiative
9.2.3. Analysis by Company and Year of Initiative
9.2.4. Analysis by Type of Initiative

9.3. Benchmark Analysis of Big Pharmaceutical Players
9.3.1. Harvey Ball Analysis: Summary of Investments Made
9.3.2. Geographical Analysis by Investments Made (Facility Specific)

10. CASE STUDY: RECENT PARTNERSHIP TRENDS
10.1. Chapter Overview
10.2. Partnership Models
10.3. CMOs with Manufacturing Facilities in China: List of Recent Partnerships
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Geography
10.4. CMOs with Manufacturing Facilities in China: Mapping Partnerships

11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. CMOs with Manufacturing Facilities in China: Installed Capacity
11.3.1. Analysis by Company Size
11.3.2. Analysis by Location of Chinese Manufacturing Facilities
11.3.2.1. Capacity Analysis: Eastern China
11.3.2.2. Capacity Analysis: Southcentral China
11.3.2.3. Capacity Analysis: Northern China

12. SWOT ANALYSIS
12.1. Chapter Overview
12.2 Strengths
12.3. Weakness
12.4. Opportunities
12.5. Threats
12.6. Comparison of SWOT Factors

13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030
13.4. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography

13.4.1. Pharmaceutical Contract Manufacturing Services Market in Eastern China, 2020-2030
13.4.2. Pharmaceutical Contract Manufacturing Services Market in Southern China, 2020-2030
13.4.3. Pharmaceutical Contract Manufacturing Services Market in Northern China, 2020-2030

13.5. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Type of Product
13.5.1. API Contract Manufacturing Services Market in China, 2020-2030
13.5.1.1. API Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography

13.5.1.1.1. API Contract Manufacturing Services Market in Eastern China, 2020-2030
13.5.1.1.2. API Contract Manufacturing Services Market in Southern China, 2020-2030
13.5.1.1.3. API Contract Manufacturing Services Market in Northern China, 2020-2030

13.5.2. Drug Product Contract Manufacturing Services Market in China, 2020-2030
13.5.2.1. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography

13.5.2.1.1. Drug Product Contract Manufacturing Services Market in Eastern China, 2020-2030
13.5.2.1.2. Drug Product Contract Manufacturing Services Market in Southern China, 2020-2030
13.5.2.1.3. Drug Product Contract Manufacturing Services Market in Northern China, 2020-2030

13.5.2.2. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Distribution by Type of Drug Product
13.5.2.2.1. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Solid Drug Product
13.5.2.2.2. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Liquid and Semi Solid Drug Product
13.5.2.2.3. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Injectable Drug Product
13.5.2.2.4. Drug product Contract Manufacturing Services Market in China, 2020-2030: Share of Other Drug Products

13.6. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Scale of Operation
13.6.1. Clinical Scale Contract Manufacturing Services Market in China, 2020-2030
13.6.2. Commercial Scale Contract Manufacturing Services Market in China, 2020-2030

13.7. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Size of Manufacturers
13.7.1. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Small Companies
13.7.2. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Mid-sized Companies
13.7.3. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Large / Very Large Companies

13.8. Concluding Remarks

14. CASE STUDY: IMPACT OF CORONAVIRUS OUTBREAK
15.1. Chapter Overview
15.2. Evaluation of Impact of COVID-19 Outbreak

15.2.1. Initiatives and Opinions of Key Players
15.2.1.1. Wuxi AppTec
15.2.1.2. Porton Pharma Solutions
15.2.1.3. Lonza

15.2.2 Impact on China Pharmaceutical CMO Market Opportunity

15.3. Key Strategies to Adopt: A Bird’s Eye View
15.3.1. Immediate Steps
15.3.2. Short / Long Term Steps

15. CONCLUSION

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Outsourcing across Various Components of the Pharmaceutical Value Chain
Figure 3.2 Range of Services Offered by CMOs
Figure 4.1 Small Molecule and Large Molecule Drugs: Comparison of Key Characteristics
Figure 4.2 Small Molecules versus Large Molecule: Comparison of Manufacturing Process
Figure 5.1 Chinese Pharmaceutical CMOs: Distribution by Year of Establishment
Figure 5.2 Chinese Pharmaceutical CMOs: Distribution by Company Size
Figure 5.3 Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Region-wise)
Figure 5.4 Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Province-wise)
Figure 5.5 Chinese Pharmaceutical CMOs: Distribution by Type of Product
Figure 5.6 Chinese Pharmaceutical CMOs: Distribution by Type of Product Manufactured and Location of Headquarters
Figure 5.7 Chinese Pharmaceutical CMOs: Highest Scale of Operation
Figure 5.8 Chinese Pharmaceutical CMOs: Distribution by Type of FDF Manufactured
Figure 5.9 Chinese Pharmaceutical CMOs: Distribution by Type of Solid FDF Manufactured
Figure 5.10 Chinese Pharmaceutical CMOs: Distribution by Type of Liquid FDF Manufactured
Figure 5.11 Chinese Pharmaceutical CMOs: Distribution by Type of Powder FDF Manufactured
Figure 5.12 Chinese Pharmaceutical CMOs: Distribution by Type of Semi-Solid FDF Manufactured
Figure 5.13 Chinese Pharmaceutical CMOs: Distribution by Type of FDF Manufactured and Geography
Figure 5.14 Chinese Pharmaceutical CMOs: Distribution by Type of Primary Packaging
Figure 5.15 Non-Chinese Pharmaceutical CMOs: Distribution by Year of Establishment
Figure 5.16 Non-Chinese Pharmaceutical CMOs: Distribution by Company Size
Figure 5.17 Non-Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Region-wise)
Figure 5.18 Non-Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Country-wise)
Figure 5.19 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Product
Figure 5.20 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Product Manufactured and Geography
Figure 5.21 Non-Chinese Pharmaceutical CMOs: Distribution by Highest Scale of Operation
Figure 5.22 Non-Chinese Pharmaceutical CMOs: Distribution by Type of FDF Manufactured
Figure 5.23 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Solid FDF Manufactured
Figure 5.24 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Liquid FDF Manufactured
Figure 5.25 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Powder FDF Manufactured
Figure 5.26 Non-Chinese Pharmaceutical CMOs: Distribution by Type of FDF Manufactured and Geography
Figure 6.1 Geographical Map Representation: Pharmaceutical CMO Manufacturing Facilities in Eastern China
Figure 6.2 Pharmaceutical CMO Manufacturing Facilities in Eastern China: Distribution by Company Size and Type of Product
Figure 6.3 Geographical Map Representation: Pharmaceutical CMO Manufacturing Facilities in Northern China
Figure 6.4 Pharmaceutical CMO Manufacturing Facilities in Northern China: Distribution by Company Size and Type of Product
Figure 6.5 Geographical Map Representation: Pharmaceutical CMO Manufacturing Facilities in Southern China
Figure 6.6 Pharmaceutical CMO Manufacturing Facilities in Southern China: Distribution by Company Size and Type of Product
Figure 7.1 Health Authorities in China and Affiliated Organizations of the CFDA
Figure 7.2 Organizational Structure of the CDE
Figure 7.3 Responsibilities of the Contract Giver
Figure 7.4 Important Aspects of the Contract
Figure 9.1 Big Pharma Benchmarking: Distribution by Number of Initiatives
Figure 9.2 Big Pharma Players: Distribution by Year of Initiative
Figure 9.3 Big Pharma Players: Distribution by Company and Year of Initiative
Figure 9.4 Big Pharma Players: Distribution by Type of Initiative
Figure 9.5 Harvey Ball Analysis: Summary of Investments Made
Figure 9.6 Big Pharma Players: Geographical Distribution by Investments Made (Facility Specific)
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-February 2020
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Local and International Distribution
Figure 10.4 Partnerships Landscape: Distribution by Year of Collaboration, Type of Collaboration and Collaborator
Figure 11.1 Pharmaceutical Contract Manufacturing Installed Capacity in China: Distribution by Size of CMOs
Figure 11.2 Pharmaceutical Contract Manufacturing Installed Capacity in China: Distribution by Location of Facility
Figure 11.3 Capacity Analysis: Contract Pharmaceutical Capacity in Eastern China
Figure 11.4 Capacity Analysis: Contract Pharmaceutical Capacity in Southcentral China
Figure 11.5 Capacity Analysis: Contract Pharmaceutical Capacity in Northern China
Figure 12.1 China Pharmaceutical Contract Manufacturing Services Market: SWOT Analysis
Figure 12.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 13.1 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Figure 13.2 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030, Distribution by Geography: Base Scenario (USD Billion)
Figure 13.3 Pharmaceutical Contract Manufacturing Services Market in Eastern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.4 Pharmaceutical Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.5 Pharmaceutical Contract Manufacturing Services Market in Northern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.6 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030, Distribution by Type of Product (USD Billion)
Figure 13.7 API Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Figure 13.8 API Contract Manufacturing Services Market in China, Distribution by Geography, 2020-2030: Base Scenario (USD Billion)
Figure 13.9 API Contract Manufacturing Services Market in Eastern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.10 API Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.11 API Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.12 Drug Product Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Figure 13.13 Drug Product Contract Manufacturing Services Market in China, Distribution by Geography, 2020-2030: Base Scenario (USD Billion)
Figure 13.14 Drug Product Contract Manufacturing Services Market in Eastern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.15 Drug Product Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.16 Drug Product Contract Manufacturing Services Market in Northern China, 2020-2030: Base Scenario (USD Billion)
Figure 13.17 Drug Product Contract Manufacturing Services Market in China, Distribution by Type of Drug Product, 2020-2030, Base Scenario (USD Billion)
Figure 13.18 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Solid Drug Product: Base Scenario (USD Billion)
Figure 13.19 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Liquid and Semi Solid Drug Product: Base Scenario (USD Billion)
Figure 13.20 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Injectable Drug Product: Base Scenario (USD Billion)
Figure 13.21 Drug product Contract Manufacturing Services Market in China, 2020-2030, Share of Other Drug Products: Base Scenario (USD Billion)
Figure 13.22 Pharmaceutical Contract Manufacturing Services Market in China, Distribution by Scale of Operation, 2020-2030, Base Scenario (USD Billion)
Figure 13.23 Clinical Scale Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Figure 13.24 Commercial Scale Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Figure 13.25 Pharmaceutical Contract Manufacturing Services Market in China, Distribution by Size of Manufacturers, 2020-2030, Base Scenario (USD Billion)
Figure 13.26 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030, Share of Small Companies: Base Scenario (USD Billion)
Figure 13.27 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030, Share of Mid-sized Companies: Base Scenario (USD Billion)
Figure 13.28 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030, Share of Large / Very Large Companies: Base Scenario (USD Billion)
Figure 14.1 Pharmaceutical Contract Manufacturing Services Market in China, 2015-2030: COVID Impact Scenario (USD Billion)
Figure 14.2 Financial Leadership vs Strategic Leadership Matrix: Evaluation of Preparedness of Companies
Figure 15.2 China Pharmaceutical Contract Manufacturing Services Market: Key Takeaways

List Of Tables

Table 3.1 Preferred Locations for Pharmaceutical CMO / CDMO Services
Table 4.1 Small Molecule and Large Molecule Drugs: Comparison of Development Characteristics
Table 5.1 List of Chinese Pharmaceutical CMOs: Information on Year of Establishment, Company Size, Location of Headquarters, Type of Product and Scale of Operation
Table 5.2 List of Chinese Pharmaceutical CMOs: Information on Type of FDF Manufactured
Table 5.3 List of Chinese Pharmaceutical CMOs: Information on Packaging Service
Table 5.4 List of Non-Chinese Pharmaceutical CMOs: Information on Year of Establishment, Company Size, Headquarter Location and Type of Product and Scale of Operation
Table 5.5 List of Chinese Pharmaceutical CMOs: Information on Type of FDF Manufactured
Table 6.1 Pharmaceutical CMO Manufacturing Facilities in China: Information on Location of Facilities
Table 6.2 Pharmaceutical CMO Manufacturing Facilities in Eastern China: Information on Location of Facilities (Province-Wise) and Core Capability
Table 6.3 Pharmaceutical CMO Manufacturing Facilities in Northern China: Information on Location of Facilities (Province-Wise) and Core Capability
Table 6.4 Pharmaceutical CMO Manufacturing Facilities in Southern China: Information on Location of Facilities (Province-Wise) and Core Capability
Table 8.1 2-Y Chem: Company Overview
Table 8.2 2Y-Chem: Pharmaceutical R&D and Manufacturing Service Offerings
Table 8.3 Aurisco Pharmaceutical: Company Overview
Table 8.4 Aurisco Pharmaceutical: R&D and Pharmaceutical Manufacturing Service Offerings
Table 8.5 ChemPartner: Company Overview
Table 8.6 ChemPartner: R&D and Pharmaceutical Manufacturing Service Offerings
Table 8.7 Dorrapharma: Company Overview
Table 8.8 Dorrapharma: R&D and Pharmaceutical Manufacturing Service Offerings
Table 8.9 Hubei Biocasue Pharmaceutical: Company Overview
Table 8.10 Hubei Biocasue Pharmaceutical: R&D and Pharmaceutical Manufacturing Service Offerings
Table 8.11 Infoark: Company Overview
Table 8.12 Ningbo Menovo Pharmaceutical: Company Overview
Table 8.13 Shandong Xinhua Pharmaceutical: Company Overview
Table 8.14 Shandong Xinhua Pharmaceutical: Pharmaceutical R&D and Manufacturing Service Offerings
Table 8.15 Shanghai Acebright Pharmaceuticals: Company Overview
Table 8.16 STA Pharmaceutical: Company Overview
Table 8.17 STA Pharmaceutical: Pharmaceutical R&D and Manufacturing Service Offerings
Table 8.18 Zhejiang Huahai Pharmaceutical: Company Overview
Table 8.19 Zhejiang Huahai Pharmaceutical: R&D and Pharmaceutical Manufacturing Service Offerings
Table 9.1 Big Pharmaceutical Players: List of Initiatives
Table 10.1 List of Partnerships, 2014-Q1 2019
Table 10.2 List of Partnerships: Information on Headquarter Location of Parent and Partner Company
Table 11.1 China Pharmaceutical Contract Manufacturing Installed Capacity: Average Capacity by Size of CMOs (Sample Data Set)
Table 11.2 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Size of CMOs
Table 11.3 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Chinese Manufacturing Facility(s)
Table 16.1 Chinese Pharmaceutical CMOs: Distribution by Year of Establishment
Table 16.2 Chinese Pharmaceutical CMOs: Distribution by Company Size
Table 16.3 Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Region-wise)
Table 16.4 Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Province-wise)
Table 16.5 Chinese Pharmaceutical CMOs: Distribution by Type of Product
Table 16.6 Chinese Pharmaceutical CMOs: Distribution by Highest Scale of Operation
Table 16.7 Chinese Pharmaceutical CMOs: Distribution by Type of FDF Manufactured
Table 16.8 Chinese Pharmaceutical CMOs: Distribution by Type of Solid FDF Manufactured
Table 16.9 Chinese Pharmaceutical CMOs: Distribution by Type of Liquid FDF Manufactured
Table 16.10 Chinese Pharmaceutical CMOs: Distribution by Type of Powder FDF Manufactured
Table 16.11 Chinese Pharmaceutical CMOs: Distribution by Type of Semi-Solid FDF Manufactured
Table 16.12 Chinese Pharmaceutical CMOs: Distribution by Type of Primary Packaging
Table 16.13 Non-Chinese Pharmaceutical CMOs: Distribution by Year of Establishment
Table 16.14 Non-Chinese Pharmaceutical CMOs: Distribution by Company Size
Table 16.15 Non-Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Region-wise)
Table 16.16 Non-Chinese Pharmaceutical CMOs: Distribution by Location of Headquarters (Country-wise)
Table 16.17 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Product
Table 16.18 Non-Chinese Pharmaceutical CMOs: Distribution by Highest Scale of Operation
Table 16.19 Non-Chinese Pharmaceutical CMOs: Distribution by Type of FDF Manufactured
Table 16.20 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Solid FDF Manufactured
Table 16.21 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Liquid FDF Manufactured
Table 16.22 Non-Chinese Pharmaceutical CMOs: Distribution by Type of Powder FDF Manufactured
Table 16.23 Pharmaceutical CMO Manufacturing Facilities in Eastern China:
Table 16.24 Pharmaceutical CMO Manufacturing Facilities in Eastern China: Distribution by Type of Product
Table 16.25 Pharmaceutical CMO Manufacturing Facilities in Northern
Table 16.26 Pharmaceutical CMO Manufacturing Facilities in Northern China: Distribution by Type of Product
Table 16.27 Pharmaceutical CMO Manufacturing Facilities in Southern China: Distribution by Company Size
Table 16.28 Pharmaceutical CMO Manufacturing Facilities in Southern China: Distribution by Type of Product
Table 16.29 Big Pharma Players: Distribution by Number of Initiatives
Table 16.30 Big Pharma Players: Distribution by Year of Initiative
Table 16.31 Big Pharma Players: Distribution by Type of Initiative
Table 16.33 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-February 2020
Table 16.34 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.35 Partnerships and Collaborations: Local and International Distribution
Table 16.36 Pharmaceutical Contract Manufacturing Installed Capacity in China: Distribution by Size of CMOs
Table 16.37 Pharmaceutical Contract Manufacturing Installed Capacity in China: Distribution by Location of Facility
Table 16.38 Capacity Analysis: Contract Pharmaceutical Capacity in Eastern China
Table 16.39 Capacity Analysis: Contract Pharmaceutical Capacity in Southcentral China
Table 16.40 Capacity Analysis: Contract Pharmaceutical Capacity in Northern China
Table 16.41 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Table 16.42 Pharmaceutical Contract Manufacturing Services Market in China, 2025 and 2030, Distribution by Geography: Base Scenario (USD Billion)
Table 16.43 Pharmaceutical Contract Manufacturing Services Market in Eastern China, 2020-2030: Base Scenario (USD Billion)
Table 16.44 Pharmaceutical Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
Table 16.45 Pharmaceutical Contract Manufacturing Services Market in Northern China, 2020-2030: Base Scenario (USD Billion)
Table 16.46 Pharmaceutical Contract Manufacturing Services Market in China, 2025 and 2030, Distribution by Type of Product (USD Billion)
Table 16.47 API Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Table 16.48 API Contract Manufacturing Services Market in China, Distribution by Geography, 2025 and 2030: Base Scenario (USD Billion)
Table 16.49 API Contract Manufacturing Services Market in Eastern China, 2020-2030: Base Scenario (USD Billion)
Table 16.50 API Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
Table 16.51 API Contract Manufacturing Services Market in Northern China, 2020-2030: Base Scenario (USD Billion)
Table 16.53 Drug Product Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Table 16.52 Drug Product Contract Manufacturing Services Market in China, Distribution by Geography, 2025 and 2030: Base Scenario (USD Billion)
Table 16.54 Drug Product Contract Manufacturing Services Market in Eastern China, 2020-2030: Base Scenario (USD Billion)
Table 16.55 Drug Product Contract Manufacturing Services Market in Southern China, 2020-2030: Base Scenario (USD Billion)
Table 16.56 Drug Product Contract Manufacturing Services Market in Northern China, 2020-2030: Base Scenario (USD Billion)
Table 16.57 Drug Product Contract Manufacturing Services Market in China, Distribution by Type of Drug Product, 2025 and 2030, Base Scenario (USD Billion)
Table 16.58 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Solid Drug Product: Base Scenario (USD Billion)
Table 16.59 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Liquid and Semi Solid Drug Product: Base Scenario (USD Billion)
Table 16.60 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Injectable Drug Product: Base Scenario (USD Billion)
Table 16.61 Drug Product Contract Manufacturing Services Market in China, 2020-2030, Share of Other Drug Products: Base Scenario (USD Billion)
Table 16.62 Pharmaceutical Contract Manufacturing Services Market in China, Distribution by Scale of Operation, 2025 and 2030, Base Scenario (USD Billion)
Table 16.63 Clinical Scale Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Table 16.64 Commercial Scale Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Base Scenario (USD Billion)
Table 16.65 Pharmaceutical Contract Manufacturing Services Market in China, Distribution by Size of Manufacturers, 2025 and 2030, Base Scenario (USD Billion)
Table 16.66 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Small Companies: Base Scenario (USD Billion)
Table 16.67 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Mid-Sized Companies: Base Scenario (USD Billion)
Table 16.68 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Large / Very Large Companies: Base Scenario (USD Billion)

List Of Companies

The following companies and organizations have been mentioned in the report:

1. 2Y-Chem
2. 3Waypharm
3. ABA Chemicals
4. AbbVie
5. Aescu Pharma
6. Agno Pharma
7. Allychem
8. Amgen
9. Anhui Biochem Biopharmaceutical
10. Anqiu Lu’an Pharmaceutical
11. Antengene 
12. Apeloa
13. APIchem 
14. APICMO
15. Ark Biosciences
16. Asymchem
17. Aurisco Pharmaceutical
18. Avery Chemical
19. Beijing Kawin Technology
20. Beijing Lunarsun Pharmaceutical
21. Beijing Mediking Biopharm
22. Beta Pharma
23. BioDuro
24. BioLingus
25. BLD Pharm
26. Bristol-Myers Squibb
27. Broad Pharmaceutical
28. C & O Pharmaceutical Technology
29. CARBOGEN AMCIS
30. Catalent Pharma Solutions
31. Changzhou Carbochem
32. Changzhou Keylab Chemical
33. ChemFuture PharmaTech
34. ChemPartner
35. Chemsigma International
36. Chemspec Chemicals
37. Chemwill Asia
38. China Pharmaceutical Research and Development Center
39. Chinese Peptide
40. Chiral Quest
41. Chongqing Huabang Shengkai Pharmaceutical
42. Chongqing Pharmaceutical Research Institute
43. Cipla
44. Codexis
45. ComWin International
46. DC Chemicals 
47. Dishman Group
48. Dizal Pharmaceutical
49. Dorrapharma
50. DSL Chemicals
51. Enantiotech
52. Enbridge PharmTech
53. EOC Pharma
54. Esteve Huayi Pharmaceutical 
55. FarmaSino Pharmaceutical 
56. Fine Industries
57. Flamma
58. Fountainbridge
59. Fresenius Kabi 
60. GIHI CHEMICALS
61. Gilead Sciences
62. GlaxoSmithKline
63. Hangzhou DayangChem
64. Hangzhou Hysen Pharma
65. Hangzhou Panyu Chemical
66. Hangzhou Pharmco
67. Hangzhou Rongda Pharm & Chem
68. HangZhou Think Chemical
69. HD Biosciences
70. Hebei BRANT Pharmaceutical 
71. Hebei Jiheng Pharmaceutical
72. Hetero
73. Hovione
74. Huayi Pharmaceuticals
75. Hubei Biocause Pharmaceutical
76. Hybio Pharmaceutical
77. Impact Therapeutics
78. Infoark
79. Jiangsu Allyrise Pharmaceutical
80. Jiangsu Baozong & Baoda Pharmachem
81. Jiangsu Hansyn Pharmaceutical
82. Jiangsu Quality Horizons Pharmtech
83. Jiangxi Fushine Pharmaceutical
84. JOINN Laboratories
85. Junye Pharmaceutical
86. Kingchem Life Sciences
87. Krka
88. Laviana Pharma
89. LEAPChem
90. Lianhetech
91. Lianhua Technology
92. Lonza 
93. Luna Chemicals
94. Medichem
95. Merck
96. Nanjing Pharmatechs
97. NFTZ Alchem International
98. Ningbo Menovo Pharmaceutical
99. Novartis
100. Novasep
101. Pfizer
102. Pfizer CentreOne
103. PharmaBlock Sciences
104. PharmAgra Labs
105. Phoenix Molecular Designs
106. Pi chemicals
107. Piramal Pharma Solutions
108. Porton Pharma Solutions
109. Prisun Pharmachem
110. Qidong Accela ChemBio
111. Qingdao Kingway Pharmtech
112. Quantum
113. Raybow Pharm
114. Roche
115. SAGECHEM 
116. Saniver 
117. Sanofi
118. SciAnda (Changshu) Pharmaceuticals
119. Seacross Pharmaceuticals
120. Shandong Keyuan Pharmaceutical 
121. Shandong Luxi Pharmaceutical
122. Shandong Xinhua Pharmaceutical
123. Shanghai Acebright Pharmaceuticals 
124. Shanghai Ansion pharma Technology
125. Shanghai Fosun Pharmaceutical
126. Shanghai Hohance Chemical
127. Shanghai Pansopharm Technology
128. Shanghai Ruiyi Medical Tech
129. Shenzhen Jianyuan Pharmaceutical Technology 
130. Siegfried 
131. Sihuan Pharmaceutical
132. Sinolite 
133. STA Pharmaceutical
134. Sundia MediTech
135. Sunwell
136. Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial
137. Suzhou Novartis Pharmaceutical Technology
138. Tai Heng Industry
139. TCI (Shanghai) Development
140. Tesaro 
141. TIEN (Tianjin) Pharmaceutical
142. Topharman Shanghai
143. Venturepharma 
144. Vesino
145. Vifor Pharma 
146. Vitruvias Therapeutic
147. ViWA
148. Viwit Pharmaceuticals
149. Wisdom Pharmaceutical
150. WuXi AppTec
151. Xianju pharma
152. XINXIANG BEST PHARMACEUTICAL 
153. YaoPharma
154. Yiling Pharmaceutical
155. Zhejiang Candorly Pharmaceutical
156. Zhejiang Changming Pharmaceutical
157. Zhejiang Dongjian Pharmaceutical 
158. Zhejiang Excel Pharmaceutical 
159. Zhejiang Haizhou Pharmaceutical
160. Zhejiang Hisun Pharmaceutical
161. Zhejiang Huahai Pharmaceutical
162. Zhejiang Jiuzhou Pharmaceutical
163. Zhejiang Langhua Pharmaceutical
164. Zhejiang Tianyu Pharmaceutical
165. Zhejiang Yongtai Technology
166. ZHIWE ChemTech